Monitor upcoming interim safety and biomarker data from upliFT-D in 1H 2026, which could serve as a near-term catalyst; the improved cash position reduces near-term dilution risk.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 3 $8.00entry
- T+1 · 9mo ago +5.50%α +4.74% · $8.44
- T+5 · 8mo ago +6.38%α +6.85% · $8.51
- T+20 · 8mo ago −1.88%α +2.53% · $7.85
- T+60 · 6mo ago −31.00%α −41.32% · $5.52
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Passage Bio reported Q4 and full-year 2025 financial results, highlighting clinical progress in its upliFT-D trial for frontotemporal dementia, including enrollment in new cohorts and a cash runway extending into Q1 2027. While R&D and net loss decreased year-over-year, no revenue was generated as the company remains pre-revenue with ongoing clinical development.
Key Financial Metrics
Key Facts
- Cash and cash equivalents were $46.3 million as of December 31, 2025, down from $76.8 million in 2024.
- R&D expenses decreased to $23.3 million in 2025 from $40.2 million in 2024.
- Net loss narrowed to $45.5 million in 2025 from $64.8 million in 2024.
- Enrolled first three FTD-GRN patients in Cohort 3 and treated first FTD-C9orf72 patient in Cohort 4 of the upliFT-D study.
- Cash runway expected through Q1 2027.
Financial Impact
Reduced cash burn with R&D down 42% YoY and net loss reduced by $19.3 million, improving financial sustainability.
Risk Factors
- Clinical trial setbacks or adverse safety events could negatively impact valuation.
- No revenue generation expected for several years as company remains in clinical development phase.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248197 |
Track record
15 reports on PASG
2 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
- Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
- Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
- Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
- Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
- Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
- Sep 2, 202610w ago 8-K Bullish 8/10 Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
- Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
- Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
- Jun 24, 202620w ago 8-K Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers